Bajaj Broking Research recommends Zydus Lifesciences and National Aluminium stocks for today. It expects Nifty to move ...

Zydus Lifesciences received final USFDA approval to manufacture Apalutamide tablets for prostate cancer, following last ...

Zydus Lifesciences rose 3% to an intra-day high of Rs 930 after the company received approval from the US FDA to manufacture ...

As per the IQVIA MAT January 2025 data, apalutamide tablets registered annual sales of $1099.80 million in the United States markets.

The rise in the Zydus Lifesciences shares came after the company received final approval from the United States Food and Drug ...

Which stocks will be in focus today including Indusind Bank, Zydus Lifesciences, Dr Reddys Laboratories, on the basis of ...

Zydus Lifesciences said that it has received final approval from the United States Food and Drug Administration (US FDA) to manufacture Apalutamide tablets, 60 mg.

On March 18, post-market hours, Zydus Lifesciences announced that it has received approval from the United States Food & Drug ...

The positive trends at GIFT Nifty futures indicate a gap-up opening for Indian equity benchmarks Sensex and Nifty.

Zydus Lifesciences shares rose 8.34 per cent on March 19, touching an intraday high of Rs 910.30  at 1:00 PM when the company ...

Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive ...